Effect of long-term hormone replacement therapy on atherosclerosis progression in postmenopausal women relates to myeloperoxidase promoter polymorphism

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 8, 2003, Pages 3823-3828

  Mäkelä, Riikka ^a   Dastidar, Prasun ^a,c   Jokela, Hannu ^a   Saarela, Marika ^a   Punnonen, Reijo ^a,c   Lehtimäki, Terho ^a,b  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL VALERATE; GESTAGEN; MYELOPEROXIDASE; SEQUENTIAL CONTRACEPTIVE AGENT;

ABDOMINAL AORTA; ADULT; AGED; ALLELE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CAROTID ARTERY; CONTROLLED STUDY; DISEASE SEVERITY; ECHOGRAPHY; FEMALE; FOLLOW UP; GENE EXPRESSION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HORMONE SUBSTITUTION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROMOTER REGION; RISK BENEFIT ANALYSIS; SCORING SYSTEM;

AGED; ALLELES; ARTERIOSCLEROSIS; DISEASE PROGRESSION; ESTROGEN REPLACEMENT THERAPY; FEMALE; HETEROZYGOTE; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; PEROXIDASE; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RISK FACTORS;

EID: 0042884465     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2002-021771     Document Type: Article

References (48)

1. Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, Mahrer PR, Selzer RH, Liu Cr CR, Liu Ch CH, Azen SP 2001 Estrogen m the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 135:939-953
2. Ross RK, Paganini-Hill A, Mack TM, Arthur M, Henderson BE 1981 Menopausal oestrogen therapy and protection from death from ischaemic heart disease. Lancet 1:858-860
3. Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, Szklo M 1993 Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. N Engl J Med 328:1069-1075
4. Chae CU, Ridker PM, Manson JE 1997 Postmenopausal hormone replacement therapy and cardiovascular disease. Thromb Haemost 78:770-780
5. Punnonen RH, Jokela HA, Dastidar PS, Nevala M, Laippala PJ 1995 Combined oestrogen-progestin replacement therapy prevents atherosclerosis in postmenopausal women. Maturitas 21:179-187
6. Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M, Rosner B, Fuchs C, Hankinson SE, Hunter DJ, Hennekens CH, Speizer FE 1997 Postmenopausal hormone therapy and mortality. N Engl J Med 336:1769-1775
7. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N 2002 Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA 288:49-57
8. Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, Furberg CD, Kowalchuk GJ, Stuckey TD, Rogers WJ, Givens DH, Waters D 2000 Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 343:522-529
9. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health initiative randomized controlled trial. JAMA 288:321-333
10. Psaty BM, Smith NL, Lemaitre RN, Vos HL, Heckbert SR, LaCroix AZ, Rosendaal FR 2001 Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. JAMA 285:906-913
11. Ross R 1999 Atherosderosis-an inflammatory disease. N Engl J Med 340:115-126
12. Klebanoff SJ 1980 Oxygen metabolism and the toxic properties of phagocytes. Ann Intern Med 93:480-489
13. Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce GL, Penn MS, Topol EJ, Sprecher DL, Hazen SL 2001 Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 286:2136-2142
14. Daugherty A, Dunn JL, Rateri DL, Heinecke JW 1994 Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 94:437-444
15. Hazell LJ, Stocker R 1993 Oxidation of low-density lipoprotein with hypochlorite causes transformation of the lipoprotein into a high-uptake form for macrophages. Biochem J 290:165-172
16. Podrez EA, Schmitt D, Hoff HF, Hazen SL 1999 Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest 103:1547-1560
17. Kutter D, Devaquet P, Vanderstocken G, Paulus JM, Marchal V, Gothot A 2000 Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit? Acta Haematol 104:10-15
18. Brennan ML, Anderson MM, Shih DM, Qu XD, Wang X, Mehta AC, Lim LL, Shi W, Hazen SL, Jacob JS, Crowley JR, Heinecke JW, Lusis AJ 2001 Increased atherosclerosis in myeloperoxidase-deficient mice. J Clin Invest 107:419-430
19. Jansson G 1991 Oestrogen-induced enhancement of myeloperoxidase activity in human polymorphonuclear leukocytes: a possible cause of oxidative stress in inflammatory cells. Free Radical Res Commun 14:195-208
20. Santanam N, Shern-Brewer R, McClatchey R, Castellano PZ, Murphy AA, Voelkel S, Parthasarathy S 1998 Estradiol as an antioxidant: incompatible with its physiological concentrations and function. J Lipid Res 39:2111-2118
21. Bekesi G, Kakucs R, Varbiro S, Feher J, Pazmany T, Magyar Z, Sprintz D, Szekacs B 2001 Induced myeloperoxidase activity and related superoxide inhibition during hormone replacement therapy. BJOG 108:474-481
22. Piedrafita FJ, Molander RB, Vansant G, Orlova EA, Pfahl M, Reynolds WF 1996 An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. J Biol Chem 271:14412-14420
23. Reynolds WF, Chang E, Douer D, Ball ED, Kanda V 1997 An allelic association implicates myeloperoxidase in the etiology of acute promyelocytic leukemia. Blood 90:2730-2737
24. Reynolds WF, Hiltunen M, Pirskanen M, Mannermaa A, Helisalmi S, Lehtovirta M, Alafuzoff I, Soininen H 2000 MPO and APOEε4 polymorphisms interact to increase risk for AD in Finnish males. Neurology 55:1284-1290
25. Reynolds WF, Rhees J, Maciejewski D, Paladino T, Sieburg H, Maki RA, Masliah E 1999 Myeloperoxidase polymorphism is associated with gender specific risk for Alzheimer's disease. Exp Neurol 155:31-41
26. Nagra RM, Becher B, Tourtellotte WW, Antel JP, Gold D, Paladino T, Smith RA, Nelson JR, Reynolds WF 1997 Immunohistochemical and genetic evidence of myeloperoxidase involvement in multiple sclerosis. J Neuroimmunol 78:97-107
27. Reynolds WF, Stegeman CA, Cohen Tervaert JW 2002-463 G/A myeloperoxidase promoter polymorphism is associated with clinical manifestations and the course of disease In MPO-ANCA-associated vasculitis. Clin Immunol 103:154-160
28. Nikpoor B, Turecki G, Fournier C, Theroux P, Rouleau GA 2001 A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am Heart J 142:336-339
29. Furberg CD, Byington RP, Borhani NA 1989 Multicenter isradipine diuretic atherosclerosis study (MIDAS). Design features. The Midas Research Group. Am J Med 86:3739
30. London SJ, Lehman TA, Taylor JA 1997 Myeloperoxidase genetic polymorphism and lung cancer risk. Cancer Res 57:5001-5003
31. Nquven T, Warnig R 1989 Improved method for separation of total HDL cholesterol and subclasses. Clin Chem 35:1086
32. Friedewald WT, Levy RI, Fredrickson DS 1972 Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502
33. Riepponen P, Marniemi J, Rautaoja T 1987 Immunoturbidimetric determination of apolipoproteins A-1 and B in serum. Scand J Clin Lab Invest 47:739-744
34. Cascorbi I, Henning S, Brockmoller J, Gephart J, Meisel C, Muller JM, Loddenkemper R, Roots I 2000 Substantially reduced risk of cancer of the aerodigestive tract in subjects with variant-463A of the myeloperoxidase gene. Cancer Res 60:644-649
35. Mikkola TS, Clarkson TB 2002 Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res 53:605-619
36. Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, Sakkinen PA, Tracy RP 1999 Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 100:717-722
37. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH 1998 Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98:731-733
38. Howard G, Sharrett AR, Heiss G, Evans GW, Chambless LE, Riley WA, Burke GL 1993 Carotid artery intimal-medial thickness distribution in general populations as evaluated by B-mode ultrasound. ARIC Investigators. Stroke 24:1297-1304
39. Cheng KS, Mikhailidis DP, Hamilton G, Seifalian AM 2002 A review of the carotid and femoral intima-media thickness as an indicator of the presence of peripheral vascular disease and cardiovascular risk factors. Cardiovasc Res 54:528-538
40. Megnien JL, Sane V, Jeannin S, Hernigou A, Plainfosse MC, Merli I, Atger V, Moatti N, Levenson J, Simon A 1992 Coronary calcification and its relation to extracoronary atherosclerosis in asymptomatic hypercholesterolemic men. The PCV METRA Group. Circulation 85:1799-1807
41. Kabutomori O, Yanagihara T, Iwatani Y, Kawarazaki A, Kabutomori M 1999 Sex difference in myeloperoxidase activity of neutrophils. Am J Hematol 60:312-313
42. Bekesi G, Magyar Z, Kakucs R, Sprintz D, Kocsis I, Szekacs B, Feher J 1999 Changes in the myeloperoxidase activity of human neutrophilic granulocytes and the amount of enzyme deriving from them under the effect of estrogen. Orv Hetil 140:1625-1630
43. Porter VR, Greendale GA, Schocken M, Zhu X, Effros RB 2001 Immune effects of hormone replacement therapy in post-menopausal women. Exp Gerontol 36:311-326
44. Heinecke JW 1998 Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidized low density lipoprotein hypothesis. Atherosclerosis 141:1-15
45. Heinecke JW 1999 Mechanisms of oxidative damage by myeloperoxidase in atherosclerosis and other inflammatory disorders. J Lab Clin Med 133:321-325
46. Bekesi G, Kakucs R, Sandor J, Sarvary E, Kocsis I, Sprintz D, Varbiro S, Magyar Z, Hrabak A, Feher J, Szekacs B 2001 Plasma concentration of myeloperoxidase enzyme in pre- and post-climacterial people: related superoxide anion generation. Exp Gerontol 37:137-148
47. Hermenegildo C, Garcia-Martinez MC, Valldecabres C, Tarin JJ, Cano A 2002 Transdermal estradiol reduces plasma myeloperoxidase levels without affecting the LDL resistance to oxidation or the LDL particle size. Menopause 9:102-109
48. Re G, Azzimondi G, Lanzarini C, Bassein L, Vaona I, Guarnieri C 1997 Plasma lipoperoxidative markers in ischaemic stroke suggest brain embolism. Eur J Emerg Med 4:5-9